These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 10568615)

  • 21. Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
    Kew OM; Sutter RW; de Gourville EM; Dowdle WR; Pallansch MA
    Annu Rev Microbiol; 2005; 59():587-635. PubMed ID: 16153180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating vaccine derived polio viruses and their impact on global polio eradication.
    Wagner BG; Earn DJ
    Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An economic analysis of poliovirus risk management policy options for 2013-2052.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Poliomyelitis eradication is a visible unsolved problem in the coming years].
    Seĭbil' VB; Malyshkina LP
    Vopr Virusol; 2011; 56(1):41-4. PubMed ID: 21427955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re:"Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative".
    Arya SC
    Am J Epidemiol; 2000 Sep; 152(6):595. PubMed ID: 10997551
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on vaccine-derived polioviruses.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses.
    Sabin AB
    Eur J Epidemiol; 1991 Mar; 7(2):95-120. PubMed ID: 1646116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication.
    Más Lago P; Cáceres VM; Galindo MA; Gary HE; Valcarcel M; Barrios J; Sarmiento L; Avalos I; Bravo JA; Palomera R; Bello M; Sutter RW; Pallansch MA; de Quadros CA
    Int J Epidemiol; 2001 Oct; 30(5):1029-34. PubMed ID: 11689516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmission dynamics of oral polio vaccine viruses and vaccine-derived polioviruses on networks.
    Kim JH; Rho SH
    J Theor Biol; 2015 Jan; 364():266-74. PubMed ID: 25264265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basic conditions for the eradication of poliomyelitis--indications for a common prescription.
    Swartz TA
    Public Health Rev; 1993-1994; 21(1-2):157-60. PubMed ID: 8041884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The scientific basis for stopping polio immunisation--issues and challenges.
    Wood DJ
    Dev Biol (Basel); 2001; 105():69-72. PubMed ID: 11763339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Policy. OPV cessation--the final step to a "polio-free" world.
    Aylward RB; Sutter RW; Heymann DL
    Science; 2005 Oct; 310(5748):625-6. PubMed ID: 16254173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards global poliomyelitis eradication: the successes and challenges for a developed country.
    Wood N; Thorley B
    J Paediatr Child Health; 2003 Dec; 39(9):647-50. PubMed ID: 14629492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.